First-line treatment of advanced ALK-positive non-small-cell lung cancer

Código QR

First-line treatment of advanced ALK-positive non-small-cell lung cancer

Shipra Gandhi,1 Hongbin Chen,2 Yujie Zhao,2 Grace K Dy2 1Department of Internal Medicine, State University of New York, 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Abstract: Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths, both within th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gandhi S, Chen H, Zhao Y, Dy GK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/67a00b2a4f4c4ec59b7bd979698c07ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016)

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
por: Berghmans T, et al.
Publicado: (2012)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns MW, et al.
Publicado: (2015)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Marianne Oulhen, et al.
Publicado: (2021)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise AM, et al.
Publicado: (2014)

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
por: Wallace Akerley, et al.
Publicado: (2021)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild SI
Publicado: (2014)

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
por: Hao-chuan Ma, et al.
Publicado: (2021)

Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami S, et al.
Publicado: (2015)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
por: Fragoulakis VF, et al.
Publicado: (2012)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Jie Zhang PhD, et al.
Publicado: (2021)

Targeted inhibition in tumors with ALK dependency
por: Kwak EL, et al.
Publicado: (2013)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Sebastian Y. F. Michels, et al.
Publicado: (2017)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Fengtan Li, et al.
Publicado: (2021)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga N, et al.
Publicado: (2015)

Emerging treatment options in the management of non-small cell lung cancer
por: Filosso PL, et al.
Publicado: (2011)

Non-small-cell lung carcinoma: role of the Notch signaling pathway
por: Barse L, et al.
Publicado: (2015)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi I, et al.
Publicado: (2014)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette W, et al.
Publicado: (2017)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
por: Gou LY, Wu YL
Publicado: (2014)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Barbara Melosky, et al.
Publicado: (2021)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study
por: Minami S, et al.
Publicado: (2015)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain RK, et al.
Publicado: (2017)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Yawen Zheng, et al.
Publicado: (2021)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou N, et al.
Publicado: (2014)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Tobias Dechow, et al.
Publicado: (2021)

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
por: Takeda M, et al.
Publicado: (2011)

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer
por: Karam SD, et al.
Publicado: (2013)

Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis
por: Ke Gong MBBS, et al.
Publicado: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
por: Gadgeel S, et al.
Publicado: (2019)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Shuluan Li, et al.
Publicado: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
por: Ke Cheng, et al.
Publicado: (2021)

Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
Publicado: (2021)